Flash Report on Revenue from Anti-Amyloid beta Antibody Leqembi®

Performance Overview

Eisai Co., Ltd. has published a flash report on global revenue for the anti-amyloid beta antibody Leqembi®. Interim period (2026-04-01 to 2026-09-30) revenue totaled 615 hundred million yen, with country breakdowns of United States 325 hundred million yen, Japan 130 hundred million yen, and China 97 hundred million yen. The prior-year same period was 411 hundred million yen, and revenues in the United States, Japan, and China in particular exceeded the prior-year levels. The earnings announcement is scheduled for November 10, 2026, and further details are expected to be disclosed at that time.

Outlook and Collaboration

For lecanemab, Eisai Co., Ltd. is leading global development and regulatory submissions, and Eisai and Biogen will conduct co-commercialization and joint promotion. Interim sales trends will be reflected in full-year 2026 performance disclosures, and detailed performance indicators and guidance are expected to be provided in the upcoming earnings announcement.